Kappa Bioscience, maker of K2VITAL vitamin K2 MK-7, has introduced a new 1% high-concentration for its K2VITAL DELTA product. DELTA is microencapsulated for enhanced stability in mineral and multivitamin formulations. AIDP is the distributor for K2VITAL DELTA 1% in the U.S. and will offer the new concentration in addition to other premium ingredients for bone and cardiovascular health.
 
Vitamin K2 is a rapidly growing market that is on pace to replicate the vitamin D3 market within a decade. Microencapsulation protection is critical for vitamin K2 when it is formulated with minerals such as calcium or magnesium. In 2012, Kappa Bioscience discovered that K2 degrades in the presence of minerals, and many K2 consumer products were not shelf-stable. With the help of BASF’s beadlet technology, Kappa launched microencapsulated K2VITAL DELTA in a 0.2% format in 2013. DELTA has gained wide acceptance in a range of dosage forms and global sales are estimated to be at approximately 12% of the K2 market.
 
The new 1% DELTA concentration is the most recent upgrade to the K2VITAL portfolio and was created to deliver advantages in formulation, storage, and cost-in-use efficiency. K2VITAL DELTA microencapsulation solves the obstacle of K2+minerals shelf stability, allowing wider K2 use with innovative co-ingredients such as KoACT collagen calcium or Magtein premium magnesium, also distributed by AIDP.

K2VITAL promotes bone and heart health by activating two proteins, which balance calcium in the body. K2 is an essential vitamin and is required in all stages of life. Vitamin K2 provides synergistic benefits to calcium, magnesium, and omega-3 product formulation and is a ‘perfect pair’ complement to vitamin D3. Healthy Aging, Joint & Mobility, and Sports Nutrition are just some of the market categories currently leveraging the bone and heart health benefits of K2. Kappa Bioscience has developed over 150 vitamin K2 product formulations that are available for license-free launch.